Title |
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
|
---|---|
Published in |
Nature Medicine, August 2022
|
DOI | 10.1038/s41591-022-01919-8 |
Pubmed ID | |
Authors |
Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, Richard Manber, Kimberly A. Walters, Lisa Kowarski, David Oakes, Eric Siemers, Karl D. Kieburtz, Maurice Zauderer |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 16 | 46% |
United Kingdom | 4 | 11% |
Italy | 1 | 3% |
New Zealand | 1 | 3% |
Germany | 1 | 3% |
Unknown | 12 | 34% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 24 | 69% |
Scientists | 8 | 23% |
Science communicators (journalists, bloggers, editors) | 3 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 11% |
Student > Ph. D. Student | 4 | 11% |
Student > Bachelor | 3 | 8% |
Student > Postgraduate | 3 | 8% |
Student > Doctoral Student | 2 | 5% |
Other | 5 | 13% |
Unknown | 17 | 45% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 4 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
Biochemistry, Genetics and Molecular Biology | 4 | 11% |
Medicine and Dentistry | 3 | 8% |
Arts and Humanities | 1 | 3% |
Other | 5 | 13% |
Unknown | 17 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 424. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2024.
All research outputs
#70,045
of 25,954,278 outputs
Outputs from Nature Medicine
#413
of 9,495 outputs
Outputs of similar age
#2,207
of 435,290 outputs
Outputs of similar age from Nature Medicine
#15
of 131 outputs
Altmetric has tracked 25,954,278 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,495 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 106.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,290 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.